检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]第三军医大学西南医院全军传染病研究所,重庆400038
出 处:《第三军医大学学报》2004年第19期1732-1734,共3页Journal of Third Military Medical University
基 金:国家自然科学基金资助项目 ( 39770 6 82 )~~
摘 要:目的 建立细胞毒性T细胞 (cytotoxicTcell ,CTL)检测体系 ,探讨丙型肝炎病毒 (hepatitisCvirus ,HCV)感染者体内CTL功能缺陷的原因。方法 选择HCV核心区多肽中对CTL有抑制作用和增强作用的多肽各 2条 ,交叉组合后共同皮下注射免疫BALB/c小鼠 ,用乳酸脱氢酶释放实验检测小鼠脾细胞CTL活性。结果 用LDH检测HCV核心区多肽免疫BALB/c小鼠的CTL活性 ,CTL活性可被CPA10 ( 5~ 2 3位氨基酸 )增强及被CPA9( 3 9~ 74位氨基酸 )抑制。CPB2 +CPB8、CPB6+CPB8组中效靶比 10∶1,2 0∶1的CTL活性显著高于对照组 ,CPB2 +CPB7、CPB6+CPB7组与对照组无明显差异 ,双因素方差分析显示HCV核心区抑制性多肽和增强性多肽有交互作用。结论 LDH可稳定检测BALB/c小鼠的CTL活性 ,HCV核心区抑制性和增强性多肽有相互作用。Objective To investigate the pathogenesis of cytotoxic T cell (CTL) dysfunction in patients with HCV infection. Methods CTL detecting system was established. Two polypeptides which could enhance CTL function and two polypeptides which could inhibit CTL function were selected and cross-combined. BALB/c mice were immunized by subcutaneous injection of the combined polypeptides, and the CTL activity in mouse spleen cells was detected by LDH release test. Results CTL activity in BLAB/c mice immunized by polypeptides in the core region of HCV could be enhanced by CPA10 (5-23 aa) and inhibited by CPA9 (39-74 aa). CTL activity in the mice could be enhanced by polypeptides from the HCV core region, CPB2+CPB8, and CPB6+CPB8, respectively. There was no obvious difference between CPB2+CPB7, CPB6+CPB7 and the negative control. Two-factor analysis of variance showed that there was reciprocal action between the inhibitory and enhancing polypeptides from the HCV core region. Conclusion CTL activity in BLAB/c mice can be detected stably by LDH. There is an interactive effect between the inhibitory and enhancing polypeptides from the HCV core region.
关 键 词:HCV核心区多肽 CTL活性 CPB BALB/C小鼠 对照组 LDH 感染者 免疫 双因素方差分析 检测体系
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.219.250.4